NVIDIA grew with the healthcare market instead of pushing into it : US Pioneer Global VC DIFCHQ NYC India Singapore – Riyadh Norway Our Mind

As the use of AI soared across healthcare, NVIDIA fit the bill in providing the necessary technology – and its stock tells the same story.

S

ince last year, NVIDIA has generated shockwaves in many industries – with healthcare being no exception.

Boasting a market cap of $2.92trn, the tech powerhouse is one of the most valuable companies in the world – and even briefly occupied the global top spot last month. Shares in NVIDIA— up about 785% since the start of 2023— paint the rise of the company and the emergence of AI.

Alongside this, NVIDIA has been expanding its presence in the healthcare sector, with activities ranging from developing drug discovery applications such as the BioNeMo tool kits to partnerships with heavyweights such as Johnson & Johnson MedTech for surgical technologies.

In an exclusive interview with Pharmaceutical Technology, NVIDIA’s EMEA business development lead for healthcare and life sciences David Ruau, talks about the company’s ever-strengthening affinity with healthcare, and how the future of the technology’s use in the sector might look amid a dynamic regulatory environment and changing public perception.

This interview has been edited for length and clarity.

See Also:

Robert Barrie [RB]: NVIDIA has made plenty of in-roads into healthcare recently. Where are the biggest opportunities in this sector?

David Ruau [DR]: I would rephrase the premise of the question. I would instead say that healthcare made in-roads into AI for treating patients, inventing new drugs, and developing new technologies in medical devices. There is a massive amount of data generated in healthcare, and that naturally led to the need to have an accelerated computing platform. And yes, NVIDIA has been ideally placed to fulfil this particular market segment because of our graphics processing unit (GPU) capabilities. The GPU, being a processing unit that allows parallel processing of data on a massive scale, is a game-changing approach. It is not that we pushed into the healthcare domain for AI, it was an emerging market, and we grew with it.

https://www.pharmaceutical-technology.com/interviews/how-nvidia-grew-with-the-healthcare-market-instead-of-pushing-into-it/